CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses expanded analysis results from the Phase III CheckMate 8HW trial (NCT04008030) of nivolumab plus ipilimumab versus chemotherapy or nivolumab monotherapy for patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Nivolumab plus ipilimumab continued to show durable progression-free survival advantages over both comparators across treatment lines, even after subsequent therapies. No new safety concerns were identified, reinforcing the use of nivolumab plus ipilimumab as a standard of care in this biomarker-defined population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next